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Abstract 
 
Parkinson’s disease (PD) and Dementia with Lewy bodies (DLB) are characterised by 
Lewy body pathology and the degeneration of midbrain-dopaminergic and cortical 
neurons, respectively. The mechanisms underlying the selective degeneration of these 
neuronal populations are not known. Gene mutations associated with PD and DLB have 
highlighted the role of oxidative stress and mitochondrial dysfunction in the pathogenesis 
of these conditions. Substitution mutations in the SNCA gene encoding alpha-synuclein are 
the most common cause of familial disease and alpha-synuclein also comprises the 
principal component of Lewy bodies. However, the contribution of this protein to 
neurodegeneration is uncertain. The intent of this thesis was to further clarify the role of 
wild type and mutant alpha-synuclein in the pathogenic mechanisms of PD and DLB.  
 
In vitro models of oxidative stress and mitochondrial dysfunction were applied to primary 
neuronal cultures derived from wild type and SNCA null rodent models. Alpha-synuclein 
expression was correlated to neuronal health, free radical production, mitochondrial 
function and metabolism. Results within this thesis demonstrate that wild-type alpha-
synuclein protects both cortical and dopaminergic neurons from oxidative stress. This 
response is linked to an increase in its cytoplasmic expression within subgroups of these 
neuronal populations. Alpha-synuclein expression did not affect free radical production but 
conferred neuroprotection against caspase-dependent apoptosis. This effect was mediated 
through the mitogen activated protein kinase (MAPK) signalling pathway. Data within this 
thesis also supports a role for alpha-synuclein in facilitating neuronal energy production 
through oxidative phosphorylation.  
  vi 
 
In contrast to wild-type protein, expression of mutant (A35T) alpha-synuclein increased 
neuronal susceptibility to oxidative toxicity. However, this mutation was not associated 
with induction of a specific apoptotic pathway. Rather mutant (A53T) alpha-synuclein was 
linked to sensitisation of neurons through a toxic gain of function which was independent 
of mitochondrial free-radical production or calcium buffering. 
 
In summary, the studies within this thesis have clarified the contribution of alpha-synuclein 
to normal neuronal function and the mechanisms of PD and DLB. The results have 
highlighted complexities surrounding the contentious role of alpha-synuclein in both 
neuroprotection and toxicity. Based on these findings, a sound hypothesis for the role of 
this protein in the pathogenesis of PD and DLB has been proposed. Significantly, this two-
hit hypothesis validates past studies, which have detailed a role of alpha-synuclein in both 
neuroprotection through chaperone activity, and in neurotoxicity through a toxic gain of 
function mechanism. This thesis will provide a basis and direction for further 
investigations into the relationship between intracellular alpha-synuclein levels, and the 
selective nature of neurodegeneration in PD and DLB. 
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